Peter Hayes, Health Research Institute, University of Limerick, Ireland
El tratamiento de los pacientes con DM1 est cambiando con la aprobacin comercial de nuevos frmacos, los mismos que buscan no tan solo un mejor control de la glicemia, tambin proteger la salud cardiovascular, y disminuir riesgo de Obesidad
Clinical trials have focused on people living with obesity, early research shows it could, if licensed, be used for conditions like type 2 diabetes and fatty liver disease
BPC-157 can be administered as an injection or an oral dosage.The duration of treatment varies based on individual needs and response to therapy
SCFAs exhibit neuroprotective effects and enhance learning and memory [152, 153]